Myasthenia Gravis Guide to Diagnosis and Treatment

Myasthenia gravis is a long-term autoimmune condition in which the immune system blocks or damages the connection between nerves and muscles, so muscles become weak and tire quickly, most often the muscles of the eyes, face, throat and limbs [1].

This page provides general information. It does not replace advice from a doctor or another qualified healthcare professional.

Key facts

The most useful thing to know about myasthenia gravis is its pattern: weakness gets worse the more a muscle is used and improves with rest, so many people are strongest in the morning and weakest by evening [8,2].
Many people notice the eyes first, with a drooping eyelid or double vision. Around 80 percent of those who start with eye symptoms alone develop weakness elsewhere within two years [3].
It is not inherited and not contagious, although occasionally more than one person in a family is affected [1].
Published prevalence figures vary widely, from 20 to 475 people per million across 94 studies, with a mean of about 173 per million [12].
Rates in older people are rising. Among people aged 65 and over in one United States analysis, prevalence rose from 81 to 119 per 100,000 between 2006 and 2019 [14].
There is no cure, though treatment works well for most people and most live to an average life expectancy [1].
Sudden difficulty breathing or swallowing is a medical emergency called a myasthenic crisis [1,6].

What is myasthenia gravis?

Every time you move, a nerve passes a message to a muscle across a tiny gap called the neuromuscular junction. The nerve ending releases acetylcholine, a chemical messenger, which crosses the gap and attaches to landing sites, called receptors, on the muscle. In myasthenia gravis the immune system makes antibodies that block or destroy those landing sites, so fewer messages get through [1]. A condition in which the immune system harms a person’s own body is autoimmune [2].

The defining feature follows from that. Each signal uses up the limited supply of working sites, so the harder a muscle works the weaker it gets, and rest lets it recover. Most people are strongest in the morning and weakest by evening [8,2]. This pattern separates myasthenia gravis from most other causes of weakness, and noticing it often leads to the diagnosis [3].

In ocular myasthenia gravis only the eye and eyelid muscles are affected [10]. In generalized myasthenia gravis the weakness reaches further, and around 80 percent of those starting with eye symptoms alone develop it within two years [3]. Other names are acquired or autoimmune myasthenia gravis. It differs from congenital myasthenic syndromes, which are inherited [1].

How common is it?

Myasthenia gravis is rare, and honest figures are harder to give than most sources suggest.

The largest review pulled together 94 studies from 1952 to 2022. Prevalence, meaning how many people live with it at one time, ranged from 20 to 475 per million, with a mean of 173. Incidence, new cases each year, ranged from 2.3 to 61.3 per million [12]. Orphanet gives 1 to 9 per 100,000 [3]. One analysis of United States insurance records estimated 316 per million among insured adults [13].

It is becoming more common in older people. Among Medicare beneficiaries aged 65 and over, prevalence rose from 81 to 119 per 100,000 between 2006 and 2019, and a United Kingdom study found the highest rate of new cases in the over-65s [14,16].

These figures count diagnosed people, mostly from health or insurance records, so they reflect how easily people reach a specialist as much as how often the condition occurs. Different methods also mean they cannot rank one region against another.

What causes it?

The cause is not known. Nothing a person did caused it, and it cannot be prevented, inherited in a simple way, or caught from another person, though occasionally two people in a family are affected [1].

Which antibody a person has matters, because it changes which treatments help:

Acetylcholine receptor antibodies, in about 85 percent of people [5]. These also switch on part of the immune system called complement, which adds to the damage [16].
MuSK antibodies, in around 5 percent. MuSK helps organize the landing sites, and thymus surgery is not used for this group [11,16].
Seronegative myasthenia gravis, in around 10 percent, where current tests find no antibody, which is not the same as none being there [11].

A small gland in the chest called the thymus is closely involved. In many people it stays enlarged into adult life, and around 1 in 10 have a thymus growth called a thymoma, usually harmless though it can become cancerous. Myasthenia gravis can start at any age, and most often begins in women under 40 and men over 60 [1,2].

What are the symptoms?

Symptoms come and go, and the condition is usually most active in the first year or two [2,16]. Common symptoms are [1,2,9]:

a drooping eyelid, on one or both sides, called ptosis
double or blurred vision
difficulty chewing, swallowing or making facial expressions
slurred speech, often after talking for a while
weak arms, legs or neck, making stairs or lifting hard
shortness of breath

All get worse with use and better after rest, so a meal can start comfortably and become hard work [2]. Antibodies can also pass from a mother to her baby, causing a temporary form that clears within months of birth [1].

When to seek urgent help. In some people the breathing muscles become too weak to move enough air. This is a myasthenic crisis and needs emergency hospital treatment [1,6]. Around 15 to 20 percent of people have at least one, often triggered by infection, stress, surgery or a medicine [1]. Call emergency services if breathing becomes difficult or swallowing fails. A crisis usually builds over days, so contact the team early when weakness is increasing [6].

How is it diagnosed?

A family doctor usually refers on, though optometrists often suspect it first, since eye symptoms come first for many people [2,10]. A neurologist, a nerve and muscle specialist, then looks for the fatigable pattern, for example by asking a person to hold an upward gaze [5].

A bedside check called the ice pack test is often used when an eyelid droops: the eyelid is measured, cooled for a few minutes, then measured again [5]. Cooling slows the enzyme that clears acetylcholine away, so more messenger stays in the gap and the eyelid lifts. That points toward myasthenia gravis without confirming it [25].

Further tests include [1,5]:

blood tests for acetylcholine receptor antibodies, then MuSK if negative, and sometimes LRP4, with newer cell-based tests finding antibodies older methods miss [16]
repetitive nerve stimulation, recording how a muscle response fades under repeated electrical pulses
single fiber electromyography, the most sensitive test, recording from individual muscle fibers
a chest CT or MRI scan to check the thymus for a thymoma, done for everyone diagnosed [3]

Diagnosis is often delayed, since weakness has many causes and test results can be unclear [1,5].

How is it treated?

There is no cure, and treatment usually controls symptoms well, with most people living to an average life expectancy [1]. Choices depend on antibody group and severity, so care is best led by an experienced team [3].

Symptom treatment. Pyridostigmine slows the breakdown of acetylcholine, so more messenger stays in the gap. Taken several times a day, it improves strength without changing the immune system [1,9].

Damping down the immune system. Corticosteroids such as prednisone are usually first, and can worsen weakness for a fortnight before improvement begins [4,9]. Steroid-sparing medicines follow, including azathioprine, mycophenolate, methotrexate and tacrolimus, which work slowly and need regular blood tests [1,9]. Rituximab is recommended early for people with MuSK antibodies who respond poorly [4].

Surgery to remove the thymus. A thymectomy is always considered when a thymoma is present [16]. Without one, the MGTX trial found people under 65 with acetylcholine receptor antibodies did better on surgery plus prednisone than prednisone alone [15,16]. Guidance suggests considering it early in people aged 18 to 50 with generalized disease and these antibodies [4].

Rescue treatment. Plasma exchange and intravenous immunoglobulin work within days and last weeks, so they are used for a crisis or before surgery [1,9].

Newer targeted medicines, both added to standard treatment. Complement inhibitors block the part of the immune system that damages the junction, and are for acetylcholine receptor antibodies only: eculizumab, ravulizumab and zilucoplan were approved in the United States in 2017, 2022 and 2023, and meningococcal vaccination is needed first [16,17,4]. FcRn blockers speed up removal of the harmful antibodies: efgartigimod was approved in 2021 for acetylcholine receptor antibodies, rozanolixizumab in 2023 and nipocalimab in 2025 for either acetylcholine receptor or MuSK antibodies [16,24]. European authorizations restrict each of the six to particular antibody groups [18,19,20,21,22,23], and access depends on local arrangements [16].

Living with myasthenia gravis

A neurology team follows most people for years, and tracking symptoms day to day shows what is normal for you [6].

Medicines that can worsen myasthenia gravis. A published list of medicines to avoid or use with caution includes some antibiotics, among them fluoroquinolones, macrolides and aminoglycosides, plus beta blockers, magnesium given into a vein, quinine, procainamide, hydroxychloroquine, statins, botulinum toxin and D-penicillamine, which is strongly linked with causing it. Immune checkpoint inhibitors used in cancer can also trigger or worsen it [4,7]. A reported link does not rule a medicine out, so the decision belongs with your doctors [7]. Tell every doctor, dentist and pharmacist before starting anything new. Live vaccines are avoided while taking medicines that suppress the immune system [4].

Emergency planning. Keep a card saying you have myasthenia gravis, a list of your medicines, the cautionary list and emergency numbers where a relative or paramedic can find them [6].

Everyday life. Pacing activity and building in rest helps, and gentle exercise may help some people [1,4]. Work and school usually need small adjustments, and in the United Kingdom the driver licensing agency must be told [9]. Some medicines need review before trying to conceive, so maternity and neurology teams should plan ahead [4]. Peer support through a myasthenia organization helps many people [8].

Thinking about a clinical trial?

Clinical trials test whether a treatment works and is safe. Myasthenia gravis is an active research area, so studies come up reasonably often [16]. Deciding is personal, and it helps to take it in steps.

1. Understand what the study is asking

Be clear on what a study involves:

what the researchers want to learn, what is being studied, and what it is compared with
how long it lasts, and what visits and tests are involved, including strength scoring, blood tests and sometimes infusions
how far you would travel, what the benefits and risks are, and what happens when the study ends

2. Consider possible medical suitability

Every trial has rules about who can take part, called eligibility criteria. Some describe who can join, others who cannot. For a myasthenia gravis study they might include a confirmed diagnosis, a specific antibody group such as acetylcholine receptor or MuSK antibodies, a score above a set level on a strength or daily-activities scale, generalized rather than ocular symptoms, stable medicine doses beforehand, and no recent thymus surgery.

trialport’s medifit helps people consider information related to possible medical suitability. It does not diagnose a condition, confirm eligibility or replace formal screening by the study team.

Explore myasthenia gravis clinical trials through trialport

3. Consider whether participation fits your life

A study can look right on paper and still be hard in practice. Worth thinking through:

the time each visit takes, how many there are, and how far you would travel, remembering that a long journey may itself leave you weaker
work, school or caring responsibilities, time off, and support from family and friends
how you feel about infusions or self-injections over months, whether you understand the study well enough to decide, and whether the timing feels right

trialport’s readifit helps people reflect on their understanding, motivation, time, routines, support, emotions and practical arrangements.

4. Ask questions before deciding

Useful questions to put to a research team:

Why is this study being carried out, and what is already known?
What exactly would I need to do, and for how long?
What are the known risks, and what is still unknown?
Could I receive a placebo? A placebo is a dummy treatment with no active medicine, used so results can be compared fairly. Would I keep my usual treatment alongside it?
Would I need vaccinations or extra blood tests first?
What happens if my symptoms get worse, and who do I contact out of hours?
Can I leave the study after joining, and what happens if I do?
Who provides my usual neurology care, and are travel costs covered?

Taking part is voluntary. A person can ask questions, speak with people they trust and choose not to participate.

Search for clinical trials at app.trialport.com.

Current research

The main areas being worked on are:

CAR T cells. Early work on these engineered immune cells has been published in small numbers of people, and its researchers call it promising but early [16].
More treatments in the same families, including further complement inhibitors and FcRn blockers, and medicines blocking signals that keep antibody-producing cells alive [16,17].
Protecting the junction early, since long-term damage there is hard to reverse, and better markers to predict who responds to which treatment [16].
Older people, where rising rates have exposed a shortage of evidence on immune treatment [16].

Study status checked: 3 August 2026. Research moves quickly, so this list will date, and not every treatment named here is approved. For current information, search at app.trialport.com.

Support and further information

In the United States, the Myasthenia Gravis Foundation of America is the main condition-specific organization, with a helpline, support groups, a symptom-tracking app and downloadable emergency and cautionary drug materials [6,7]. The NINDS overview is a reliable government summary [1].

In the United Kingdom, myaware is the charity for the myasthenias, with information sheets on each medicine and groups for adults, young people and carers [8,9]. The NHS pages give a short overview [2].

In Canada, the Myasthenia Gravis Society of Canada offers peer support in English and French [28], and in Australia Myasthenia Alliance Australia brings together the state associations [29]. Coverage elsewhere is uneven, and Orphanet lists organizations and specialist centers by country [3].

Well-known people

Suzanne Rogers, the actress who has played Maggie Horton on Days of Our Lives since 1973, was diagnosed in 1984 after weakness affected her swallowing and speech. She was treated with pyridostigmine, azathioprine and prednisone, had a thymectomy and went into remission, and asked the writers to give her character the same condition [26].

Monica Seles, the nine-time Grand Slam tennis champion, said in 2025 that she had been diagnosed three years earlier, noticing it while hitting a ball with family: “I was like, yeah, I see two balls” [27].

Weakness has many causes, so this page names only people who have described this condition publicly themselves.

Questions people often ask

Why is my weakness worse in the evening?
Each signal uses up the limited number of working landing sites, so weakness builds through the day and rest lets it recover [8,2].

Will it spread beyond my eyes?
It may not. Around 80 percent of people who start with eye symptoms alone develop weakness elsewhere within two years [3,2].

Does the antibody result change my treatment?
Yes. Thymus surgery and complement inhibitors are for acetylcholine receptor antibodies, while rituximab is recommended early for MuSK [4,16].

Does myasthenia gravis shorten life?
For most people it does not significantly affect life expectancy, though a crisis can be life-threatening if untreated [2].

Can it go away?
Symptoms can improve or disappear for long periods, and some people stop medicines after discussing it with their doctor. Permanent remission is uncommon [1,2].

Sources

National Institute of Neurological Disorders and Stroke (NINDS). Myasthenia Gravis. Last reviewed 13 March 2026. https://www.ninds.nih.gov/health-information/disorders/myasthenia-gravis Accessed 3 August 2026.
NHS. Myasthenia gravis: Overview. Page last reviewed 13 September 2023. https://www.nhs.uk/conditions/myasthenia-gravis/ Accessed 3 August 2026.
Orphanet. Myasthenia gravis. ORPHA:589. Last update May 2026, expert reviewer Dr Lorenzo Maggi, EURO-NMD. https://www.orpha.net/en/disease/detail/589 Accessed 3 August 2026.
Narayanaswami P, Sanders DB, Wolfe G, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology. 2021;96(2):114-122. doi:10.1212/WNL.0000000000011124. https://www.aanem.org/docs/default-source/documents/practice/international-consesus-guidance-for-management-of-myasthenia-gravis.pdf Accessed 3 August 2026.
Myasthenia Gravis Foundation of America. Diagnosing MG. https://myasthenia.org/what-is-mg/diagnosing-mg/ Accessed 3 August 2026.
Myasthenia Gravis Foundation of America. MG Emergencies. https://myasthenia.org/what-is-mg/mg-emergencies/ Accessed 3 August 2026.
Myasthenia Gravis Foundation of America. Cautionary Drugs. https://myasthenia.org/living-with-mg/cautionary-drugs/ Accessed 3 August 2026.
myaware. What is myasthenia? Updated 2 April 2025. https://www.myaware.org/what-is-myasthenia Accessed 3 August 2026.
myaware. Myasthenia Gravis. Updated 31 May 2024. https://www.myaware.org/myasthenia-gravis Accessed 3 August 2026.
myaware. Ocular Myasthenia. Updated 31 May 2024. https://www.myaware.org/ocular-myasthenia Accessed 3 August 2026.
myaware. Antibodies and Seronegative. Updated 29 July 2025. https://www.myaware.org/antibodies-and-seronegative Accessed 3 August 2026.
Sciancalepore F, Lombardi N, Valdiserra G, et al. Prevalence, Incidence, and Mortality of Myasthenia Gravis and Myasthenic Syndromes: A Systematic Review. Neuroepidemiology. 2025;59(5):579-592. doi:10.1159/000539577. https://pubmed.ncbi.nlm.nih.gov/39380477/ Accessed 3 August 2026.
Ye Y, Murdock DJ, Chen C, Liedtke W, Knox CA. Epidemiology of myasthenia gravis in the United States. Frontiers in Neurology. 2024;15:1339167. doi:10.3389/fneur.2024.1339167. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10907989/ Accessed 3 August 2026.
Bruckman D, Lee I, Schold JD, et al. Epidemiologic Study of Myasthenia Gravis in the Elderly US Population: A Longitudinal Analysis of the Medicare Claims Database, 2006-2019. Neurology. 2024;103(10):e210005. doi:10.1212/WNL.0000000000210005. https://pubmed.ncbi.nlm.nih.gov/39496108/ Accessed 3 August 2026.
Wolfe GI, Kaminski HJ, Aban IB, et al. Randomized Trial of Thymectomy in Myasthenia Gravis. New England Journal of Medicine. 2016;375(6):511-522. doi:10.1056/NEJMoa1602489. https://pubmed.ncbi.nlm.nih.gov/27509100/ Accessed 3 August 2026.
Binks SNM, Morse IM, Ashraghi M, Vincent A, Waters P, Leite MI. Myasthenia gravis in 2025: five new things and four hopes for the future. Journal of Neurology. 2025;272(3):226. doi:10.1007/s00415-025-12922-7. https://pmc.ncbi.nlm.nih.gov/articles/PMC11846739/ Accessed 3 August 2026.
European Academy of Neurology. What’s new for myasthenia gravis in 2025. 2 July 2025. https://www.ean.org/research/resources/neurology-updates/detail/whats-new-for-myasthenia-gravis-in-2025 Accessed 3 August 2026.
European Medicines Agency. Soliris (eculizumab): overview. https://www.ema.europa.eu/en/medicines/human/EPAR/soliris Accessed 3 August 2026.
European Medicines Agency. Ultomiris (ravulizumab): overview. https://www.ema.europa.eu/en/medicines/human/EPAR/ultomiris Accessed 3 August 2026.
European Medicines Agency. Zilbrysq (zilucoplan): overview. Marketing authorization 1 December 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/zilbrysq Accessed 3 August 2026.
European Medicines Agency. Vyvgart (efgartigimod alfa): overview. Marketing authorization 10 August 2022. https://www.ema.europa.eu/en/medicines/human/EPAR/vyvgart Accessed 3 August 2026.
European Medicines Agency. Rystiggo (rozanolixizumab): overview. Marketing authorization 5 January 2024. https://www.ema.europa.eu/en/medicines/human/EPAR/rystiggo Accessed 3 August 2026.
European Medicines Agency. Imaavy (nipocalimab): overview. Marketing authorization 28 November 2025. https://www.ema.europa.eu/en/medicines/human/EPAR/imaavy Accessed 3 August 2026.
Johnson & Johnson. Johnson & Johnson receives FDA approval for IMAAVY (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG). Press release, 30 April 2025. https://www.prnewswire.com/news-releases/johnson–johnson-receives-fda-approval-for-imaavy-nipocalimab-aahu-a-new-fcrn-blocker-offering-long-lasting-disease-control-in-the-broadest-population-of-people-living-with-generalized-myasthenia-gravis-gmg-302442650.html Accessed 3 August 2026.
Conceição C, Ferreira J, Rebelo V, Pinto R. Unilateral Ptosis in a 72-Year-Old Male: Early Diagnosis of Myasthenia Gravis Using the Ice Pack Test. Cureus. 2024;16(11):e73581. doi:10.7759/cureus.73581. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11645178/ Accessed 3 August 2026.
Brain & Life (American Academy of Neurology). Soap Opera Star Suzanne Rogers Brings Awareness to Myasthenia Gravis. Brain & Life Podcast. https://www.brainandlife.org/podcast/soap-opera-star-suzanne-rogers-brings-awareness-myasthenia-gravis Accessed 3 August 2026.
NBC News (reporting an Associated Press interview). Tennis star Monica Seles reveals her diagnosis with myasthenia gravis. 12 August 2025. https://www.nbcnews.com/sports/tennis/tennis-star-monica-seles-reveals-diagnosis-myasthenia-gravis-rcna224605 Accessed 3 August 2026.
Myasthenia Gravis Society of Canada. Who We Are. https://mgcanada.org/about-us/who-we-are/ Accessed 3 August 2026.
Myasthenia Alliance Australia. About MAA. https://myastheniaalliance.org.au/about-maa/ Accessed 3 August 2026.

Review information

Written by: trialport editorial team
Reviewed by: Keith Berelowitz, Founder and CEO, trialport
Reviewed on: 3 August 2026
Next review due: 3 August 2027
References last checked: 3 August 2026

Myasthenia gravis: a plain-language guide